Stocks
Amgen Analysts Set Price Targets Between $380-$457
On September 17th, major Wall Street analysts updated their ratings for Amgen (AMGN.US), with price targets ranging from $380 to $457.
Citi analyst Geoff Meacham maintained a hold rating and kept the target price at $405. Meanwhile, Barclays analyst Emily Field also held a hold rating but adjusted her target price from $350 to $380.
On the other hand, William Blair analyst Matt Phipps and Piper Sandler analyst David Amsellem both maintained buy ratings, with Phipps keeping his target price at $457. Trist Financial analyst Gregory Renza also held a hold rating.